Related Experiment Videos
[Paroxetine withdrawal syndrome].
L Belloeuf1, C Le Jeunne, F C Hugues
1Service de Médecine Interne et de Thérapeutique, Hôpital Laennec, Paris.
Annales De Medecine Interne
|June 16, 2000
Summary
Serotonin re-uptake inhibitor withdrawal syndrome, particularly with paroxetine, presents unique clinical features. Gradual dose reduction and patient education are key to preventing and managing this common antidepressant discontinuation syndrome.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Selective serotonin reuptuptake inhibitors (SSRIs) are widely prescribed antidepressants.
- Physician awareness of SSRI withdrawal syndrome, especially with paroxetine, remains limited.
- Variable incidence and clinical presentations complicate diagnosis and management.
Observation:
- SSRI withdrawal symptoms typically emerge within 24-48 hours of discontinuation.
- Peak symptom intensity occurs around day 5, with resolution usually within 2-3 weeks.
- Short half-life SSRIs like paroxetine and fluvoxamine are associated with higher withdrawal incidence.
Findings:
- Common symptoms include dizziness, vertigo, headache, nausea, flu-like symptoms, anxiety, confusion, irritability, insomnia, and vivid dreams.
- Withdrawal severity correlates with daily dosage and duration of SSRI treatment.
- Risk factors include poor compliance, prior withdrawal history, polypharmacy, and alcohol use.
Implications:
- Preventive strategies involve gradual dose tapering and comprehensive patient education.
- Reintroducing the SSRI followed by a slow taper is recommended for managing existing withdrawal symptoms.
- Enhanced physician education on SSRI withdrawal is crucial for improved patient care and treatment adherence.